Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 12/20 | 0.79 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 0.75 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.75 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.75 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.75 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.75 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.75 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.75 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.75 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.75 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.75 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.75 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.75 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.75 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.75 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.75 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.75 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.75 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30061342 | 1.00 | HTR4 (0.79) | HTR4DRD4CYP3A4CYP1A2ADRA2A | |
| SCHEMBL6840623 | 0.99 | HTR4 (0.80) | HTR4DRD4CYP3A4CYP1A2ADRA2A | |
| SCHEMBL6840670 | 0.95 | HTR4 (0.76) | HTR4DRD4CYP3A4CYP1A2ADRA2A | |
| SCHEMBL9021864 | 0.93 | DRD4 (0.77) | HTR4DRD4CYP3A4CYP1A2ADRA2A | |
| Hydrochloric Acid SCHEMBL9021484 | 0.90 | HTR4 (0.80) | HTR4DRD4CYP3A4CYP1A2ADRA2A | |
| SCHEMBL9021668 | 0.89 | HTR4 (0.81) | HTR4DRD4CYP3A4CYP1A2ADRA2A | |
| Hydrochloric Acid SCHEMBL6841284 | 0.88 | HTR4 (0.76) | HTR4DRD4CYP3A4CYP1A2ADRA2A | |
| Hydrochloric Acid SCHEMBL9021661 | 0.88 | HTR4 (0.79) | HTR4DRD4CYP3A4CYP1A2ADRA2A | |
| Hydrochloric Acid SCHEMBL6840714 | 0.87 | HTR4 (0.72) | HTR4DRD4CYP3A4CYP1A2ADRA2A | |
| Hydrochloric Acid SCHEMBL9022167 | 0.87 | HTR4 (0.81) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087622-A1 | Benzamide derivative and medicament containing the same | KATO HIDEO (JP) | 2004-05-06 | — | — | US | disclosed |
| US-6638951-B1 | Medicament has excellent enhancing action on gastrointestinal tract motility, and is orally available with reduced side effects, the agent for therapeutic treatment of digestive diseases, an agent for improving function of gastrointestinal | HOKURIKU SEIYAKU CO., LTD. (JP) | 2003-10-28 | — | — | US | disclosed |
| EP-1149832-B1 | BENZAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME | HOKURIKU PHARMACEUTICAL (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-1149832-A1 | BENZAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME | HOKURIKU SEIYAKU CO., LTD. (JP) | 2001-10-31 | — | — | EP | disclosed |
| EP-0640601-B1 | BENZAMIDE DERIVATIVE | HOKURIKU PHARMACEUTICAL (JP) | 1996-12-04 | — | — | EP | disclosed |
| US-5500422-A | FOR TREATING GASTROINTESTINAL DISEASES | HOKURIKU SEIYAKU CO. LTD. (JP) | 1996-03-19 | — | — | US | disclosed |
| US-5395832-A | Gastrointestinal disorders | HOKURIKU SEIYAKU CO., LTD. (JP) | 1995-03-07 | — | — | US | disclosed |
| EP-0640601-A1 | BENZAMIDE DERIVATIVE | HOKURIKU SEIYAKU CO., LTD. (JP) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087622-A1 | Benzamide derivative and medicament containing the same | SLC10A2, FABP2, HDAC6 | HTR4 598/4885DRD4 1433/4885ADRA2A 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.